ArticleCancer research2013
Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma.
Article in Cancer research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 61 citations in OpenAlex.
- Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.Blood · 2018Trial
- Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.The New England journal of medicine · 2015Trial
- Anti-angiogenesis in human lymphomas. New insights.Frontiers in oncology · 2025Review
- Macrophages and angiogenesis in human lymphomas.Clinical and experimental medicine · 2024Review
- Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.Frontiers in immunology · 2024Review
- Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma.Blood advances · 2023Article
- Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma.Blood advances · 2023Article
- Blockade of CCR1 induces a phenotypic shift in macrophages and triggers a favorable antilymphoma activity.Blood advances · 2023Article
- Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma.Cellular oncology (Dordrecht, Netherlands) · 2023Article
- The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition.Haematologica · 2022Article
- Review
- Advances in 3D Vascularized Tumor-on-a-Chip Technology.Advances in experimental medicine and biology · 2022Article
- Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms.Frontiers in immunology · 2022Review
- Review
- Sequencing of Novel Therapies for Mantle Cell Lymphoma.Current treatment options in oncology · 2021Review
- Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas.World journal of clinical oncology · 2021Review
- Non-chemotherapy Options for Newly Diagnosed Mantle Cell Lymphoma.Current treatment options in oncology · 2021Review
- Immunomodulatory Drugs for the Treatment of B Cell Malignancies.International journal of molecular sciences · 2021Review
- Management of Older Adults with Mantle Cell Lymphoma.Drugs & aging · 2020Review
- Emerging therapies in mantle cell lymphoma.Journal of hematology & oncology · 2020Review
Corrections and comments
- Erratum issuedChen, Hong [added]
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
Abstract
Lymphomas originate in and spread primarily along the lymphatic system. However, whether lymphatic vessels contribute to the growth and spreading of lymphomas is largely unclear. Mantle cell lymphoma (MCL) represents an aggressive non-Hodgkin's lymphoma. We found that MCL exhibited abundant intratumor lymphatic vessels. Our results demonstrated that the immunomodulatory drug lenalidomide potently inhibited the growth and dissemination of MCL in a xenograft MCL mouse model, at least in part, by inhibiting functional tumor lymphangiogenesis. Significant numbers of tumor-associated macrophages expressing vascular endothelial growth factor-C were found in both human MCL and mouse MCL xenograft samples. Lenalidomide treatment resulted in a significant reduction in the number of MCL-associated macrophages. In addition, in vivo depletion of monocytes/macrophages impaired functional tumor lymphangiogenesis and inhibited MCL growth and dissemination. Taken together, our results indicate that tumor lymphangiogenesis contributes to the progression of MCL and that lenalidomide is effective in decreasing MCL growth and metastasis most likely by inhibiting recruitment of MCL-associated macrophages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.